Lorcaserin
- Generic Name
- Lorcaserin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H14ClN
- CAS Number
- 616202-92-7
- Unique Ingredient Identifier
- 637E494O0Z
- Background
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.
- Indication
For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
- Associated Conditions
- Obesity
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT02129608
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02022956
- Locations
- 🇺🇸
Worlwide Clinical Trials, San Antonio, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
- Conditions
- OverweightType 2 DiabetesCardiovascular DiseaseHigh Cardiovascular RiskObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14673
- Registration Number
- NCT02019264
- Locations
- 🇺🇸
InterMed, PA, Portland, Maine, United States
🇺🇸Interventional Cardiac Consultants, Trinity, Florida, United States
🇺🇸Spectrum Clinical Research, Baltimore, Maryland, United States
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
- Conditions
- Chronic Weight Management
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT01987427
- Locations
- 🇺🇸
Scripps Clinical Research Center, La Jolla, California, United States
🇺🇸Radiant Research - Dallas, Dallas, Texas, United States
🇺🇸National Clinical Research - Norfolk, Norfolk, Virginia, United States
Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2014-01-30
- Target Recruit Count
- 15
- Registration Number
- NCT01962402
- Locations
- 🇺🇸
VA Long Beach, Long Beach, California, United States
Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users
- Conditions
- HealthyDrug Abuse
- Interventions
- Drug: PlaceboDrug: Active Comparator #1Drug: Active Comparator #2Drug: Active Comparator #3
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00828659
- Locations
- 🇨🇦
Kendle Early Phase, Toronto, Toronto, Ontario, Canada
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00829140
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00828438
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00828724
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00828932
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.